Literature DB >> 24237978

Evaluation and treatment of transfusional iron overload in children.

Hannah M Ware1, Janet L Kwiatkowski.   

Abstract

Red blood cell transfusions are increasingly used in the management of various anemias, including thalassemia and sickle cell disease. Because the body lacks physiologic mechanisms for removing excess iron, transfusional iron overload is a common complication in children receiving regular transfusions. Iron chelation is necessary to remove the excess iron that causes injury to the heart, liver, and endocrine organs. Three chelators, deferoxamine, deferasirox, and deferiprone, are currently available in the United States. When choosing a chelator regimen, patients, parents, and providers may consider a variety of factors, including the severity of iron overload, administration schedule, and adverse effect profile.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chelation; Iron overload; Magnetic resonance imaging; Transfusion

Mesh:

Substances:

Year:  2013        PMID: 24237978     DOI: 10.1016/j.pcl.2013.09.003

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  14 in total

1.  Retrospective comparison of gradient recalled echo R2* and spin-echo R2 magnetic resonance analysis methods for estimating liver iron content in children and adolescents.

Authors:  Suraj D Serai; Robert J Fleck; Charles T Quinn; Bin Zhang; Daniel J Podberesky
Journal:  Pediatr Radiol       Date:  2015-05-26

2.  Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia.

Authors:  Sherif M Badawy; Kerry Morrone; Alexis Thompson; Tonya M Palermo
Journal:  Cochrane Database Syst Rev       Date:  2019-06-28

3.  Can multi-slice or navigator-gated R2* MRI replace single-slice breath-hold acquisition for hepatic iron quantification?

Authors:  Ralf B Loeffler; M Beth McCarville; Anne W Wagstaff; Matthew P Smeltzer; Axel J Krafft; Ruitian Song; Jane S Hankins; Claudia M Hillenbrand
Journal:  Pediatr Radiol       Date:  2016-10-17

4.  Socio-demographic Profile and Economic Burden of Treatment of Transfusion Dependent Thalassemia.

Authors:  Amita Moirangthem; Shubha R Phadke
Journal:  Indian J Pediatr       Date:  2017-11-09       Impact factor: 1.967

5.  Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia.

Authors:  Sherif M Badawy; Kerry Morrone; Alexis Thompson; Tonya M Palermo
Journal:  Cochrane Database Syst Rev       Date:  2017-12-14

Review 6.  Transfusion and Cellular Therapy in Pediatric Sickle Cell Disease.

Authors:  Yan Zheng; Stella T Chou
Journal:  Clin Lab Med       Date:  2020-12-24       Impact factor: 1.935

7.  Carvedilol improves left ventricular diastolic dysfunction in patients with transfusion-dependent thalassemia.

Authors:  Suchaya Silvilairat; Pimlak Charoenkwan; Suwit Saekho; Adisak Tantiworawit; Nipon Chattipakorn
Journal:  Ann Pediatr Cardiol       Date:  2021-05-03

8.  H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice.

Authors:  Gregory M Vercellotti; Fatima B Khan; Julia Nguyen; Chunsheng Chen; Carol M Bruzzone; Heather Bechtel; Graham Brown; Karl A Nath; Clifford J Steer; Robert P Hebbel; John D Belcher
Journal:  Front Pharmacol       Date:  2014-04-17       Impact factor: 5.810

9.  Cardiac and Hepatic T2*-Weighted Magnetic Resonance Imaging in Transfusion Dependent Hemoglobinopathy in North West of Iran.

Authors:  N Valizadeh; V Alinejad; S Hejazi; M Noroozi; A Hashemi; B Rahimi; Sh Nateghi
Journal:  Iran J Ped Hematol Oncol       Date:  2015-12-10

10.  Heart Rate Variability for Early Detection of Cardiac Iron Deposition in Patients with Transfusion-Dependent Thalassemia.

Authors:  Suchaya Silvilairat; Pimlak Charoenkwan; Suwit Saekho; Adisak Tantiworawit; Arintaya Phrommintikul; Somdet Srichairatanakool; Nipon Chattipakorn
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.